DEVELOPMENT SAFETY UPDATE REPORT RASMIR 1.8.2022– 31.7.2023

DEMLOVÁ, Regina and Michaela KUBELOVÁ. DEVELOPMENT SAFETY UPDATE REPORT RASMIR 1.8.2022– 31.7.2023. NA. Brno: MU LF/MŠMT/MOÚ, 2023, 16 pp. NA.

Basic information

• Original name: DEVELOPMENT SAFETY UPDATE REPORT RASMIR 1.8.2022– 31.7.2023
• Name in Czech: DEVELOPMENT SAFETY UPDATE REPORT RASMIR 1.8.2022– 31.7.2023
• Authors: DEMLOVÁ, Regina (203 Czech Republic, guarantor) and Michaela KUBELOVÁ (203 Czech Republic, belonging to the institution).
• Edition: NA. Brno, 16 pp. NA, 2023.
• Publisher: MU LF/MŠMT/MOÚ

Other information

• Original language: English
• Type of outcome: Research report
• Field of Study: 30230 Other clinical medicine subjects
• Country of publisher: Czech Republic
• Confidentiality degree: is not subject to a state or trade secret
• WWW: RASMIR
• RIV identification code: RIV/00216224:14110/23:00133170
• Organization unit: Faculty of Medicine
• Keywords (in Czech): metastatický kolorektální karcinom; wild-type KRAS / NRAS; miR-31-5p; RASmiR; klinická studie
• Keywords in English: metastatic colorectal cancer; wild-type KRAS / NRAS; miR-31-5p; RASmiR; clinical study
• Tags: interim report, MOÚ, MU, RIV, user

Abstract

Rational Anti-EGFR therapy Selection for the first-line treatment of patients with metastatic KRAS/NRAS wild type colorectal cancer based on the use of molecular predictor miR-31-5p (RASmiR) Phase II. This is the fourth annual DSUR for the RASmiR trial summarising safety data received by the Sponsor from August 1, 2022 – July 31, 2023. Clinical trial RASmiR is a multicenter, open label, single-arm, phase II trial. During the period under review, 30 patients were enrolled to the study.

Links

• 90249, large research infrastructures: Name: CZECRIN IV